Announcements Trials
Browse Landscape

Phase

Phase 4 1Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1Genitourinary 1Dermatologic 1Breast 1

Conditions

Subcutaneous panniculitis-like T-cell lymphoma 1Immunoblastic Lymphadenopathy 1Enteropathy-Associated T-Cell Lymphoma 1

Interventions

Cyclophosphamide 27Vincristine 24Dexamethasone 22Rituximab 21Methotrexate 21Cytarabine 21Mercaptopurine 16Doxorubicin 15Etoposide 13Asparaginase 13Daunorubicin 12Prednisone 10Prednisolone 10Granulocyte Colony-Stimulating Factor 10Ifosfamide 8Idarubicin 8fludarabine 7pegylated granulocyte colony-stimulating factor 6Thioguanine 6Teniposide 6Vindesine 5Brentuximab Vedotin 5ibrutinib 4fludarabine phosphate 4Stem Cell Transplantation 4Gemcitabine 4Cisplatin 4Aprepitant 4zanubrutinib 3prednylidene 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 4 × pirarubicin × Lymphoid × Clear all
NCT01746992 2017-11-14

CTOP/ITE/MTX Compared With CHOP as the First-line Therapy for Newly Diagnosed Young Patients With T Cell Lymphoma

Ruijin Hospital

Phase 4 Unknown
200 enrolled
DermatologicLymphoid

Subcutaneous panniculitis-like T-cell lymphoma, Immunoblastic Lymphadenopathy, Enteropathy-Associated T-Cell Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡